NutriBand Selects Commercial Brand Name for Lead Fentanyl Patch, Advancing Regulatory Path

summarizeSummary

NutriBand Inc. has selected a commercial brand name for its lead abuse-deterrent fentanyl patch, a key milestone in its regulatory and commercialization strategy, with significant market potential.

check_boxKey Events

• Commercial Brand Name Selected

  NutriBand Inc. has chosen a worldwide commercial brand name for its lead product, an abuse-deterrent fentanyl transdermal system, which utilizes its proprietary AVERSA™ technology.

• Regulatory Submissions Initiated

  The selected brand name and product labeling will be submitted to the FDA and other international regulatory agencies for review and approval, alongside trademark registration with the United States Patent and Trademark Office (USPTO).

• Significant Market Potential Identified

  The company estimates its abuse-deterrent fentanyl transdermal system has the potential to reach peak annual US sales of $80 million to $200 million.

• Strategic Naming Partnership

  NutriBand partnered with Brand Institute, Inc., a global leader in pharmaceutical brand name development, and its regulatory subsidiary, Drug Safety Institute, to develop the brand name and ensure regulatory compliance.

auto_awesomeAnalysis

NutriBand's selection of a commercial brand name for its lead abuse-deterrent fentanyl patch marks a critical step towards regulatory approval and commercialization. For a company with a market capitalization of approximately $46 million, the projected peak annual US sales of $80 million to $200 million represent a potentially transformative opportunity. This development, supported by a partnership with a leading pharmaceutical branding firm, signals significant progress in bringing a high-value product to market and could substantially de-risk the company's future prospects.